Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations

Clinical Immunology

Volumn 151, Issue 2, 2014, Pages 127-135

  Miyazaki, Yusei ^a   Niino, Masaaki ^a   Fukazawa, Toshiyuki ^b   Takahashi, Eri ^a   Nonaka, Takayuki ^a   Amino, Itaru ^a   Tashiro, Jun ^a   Minami, Naoya ^a   Fujiki, Naoto ^a   Doi, Shizuki ^a   Kikuchi, Seiji ^a  

^a HOKKAIDO MEDICAL CENTER   (Japan)

^b Sapporo Neurology Clinic   (Japan)

Author keywords

B cells; CD80; Cytokine; Fingolimod; Multiple sclerosis; Transitional B cells

Indexed keywords

B7 ANTIGEN; FINGOLIMOD; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CELL COMPARTMENTALIZATION; CHEMOTAXIS ASSAY; CIRCULATION; CLINICAL ARTICLE; CLINICAL OBSERVATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; MIDDLE AGED; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; REMISSION;

B CELLS; CD80; CYTOKINE; FINGOLIMOD; MULTIPLE SCLEROSIS; TRANSITIONAL B CELLS;

ADULT; ANTIGENS, CD80; B-LYMPHOCYTE SUBSETS; CASE-CONTROL STUDIES; CHEMOTAXIS, LEUKOCYTE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-10; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; RECEPTORS, CCR7; SPHINGOSINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84895742456     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.02.001     Document Type: Article

References (36)

1. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., et al. The Immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 2002, 277:21453-21457.
2. Gräler M.H., Goetzl E.J. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors. FASEB J. 2004, 18:551-553.
3. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002, 296:346-349.
4. Mehling M., Johnson T.A., Antel J., Kappos L., Bar-Or A. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 2011, 76:S20-S27.
5. Ingwersen J., Aktas O., Kuery P., Kieseier B., Boyko A., Hartung H.P. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin. Immunol. 2012, 142:15-24.
6. Mehling M., Brinkmann V., Antel J.P., Bar-Or A., Goebels N., Vedrine C., et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008, 71:1261-1267.
7. + T cells in FTY720-treated patients with multiple sclerosis. Arch. Neurol. 2010, 67:1449-1455.
8. Vaessen L.M., van Besouw N.M., Mol W.M., Ijzermans J.N., Weimar W. FTY720 treatment of kidney transplant patients: a differential effect on B cells, naïve T cells, memory T cells and NK cells. Transpl. Immunol. 2006, 15:281-288.
9. Mehling M., Lindberg R., Raulf F., Kuhle J., Hess C., Kappos L., et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010, 75:403-410.
10. bright NK lymphocyte subset in FTY720-treated multiple sclerosis patients. J. Immunol. 2011, 187:570-579.
11. Bar-Or A., Calabresi P.A.J., Arnold D., Markowitz C., Shafer S., Kasper L.H., et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann. Neurol. 2008, 63:395-400.
12. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
13. Kappos L., Li D., Calabresi P.A., O'Connor P., Bar-Or A., Barkhof F., et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011, 378:1779-1787.
14. Cross A.H., Stark J.L., Lauber J., Ramsbottom M.J., Lyons J.A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 2006, 180:63-70.
15. + B-cells in stable renal allograft recipients. Int. Immunopharmacol. 2007, 7:88-95.
16. Kowarik M.C., Pellkofer H.L., Cepok S., Korn T., Kumpfel T., Buck D., et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011, 76:1214-1221.
17. Biajoux V., Bignon A., Freitas C., Martinez V., Thelen M., Lima G., et al. Expression of CXCL12 receptors in B cells from Mexican Mestizos patients with systemic lupus erythematosus. J. Transl. Med. 2012, 10:251.
18. Duddy M.E., Alter A., Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation?. J. Immunol. 2004, 172:3422-3427.
19. Duddy M., Niino, Adatia F., Hebert S., Freedman M., Atkins H., et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 2007, 178:6092-6099.
20. + T-cell proliferation and IFN-γ production in response to MBP and MOG. Eur. J. Immunol. 2010, 40:2942-2956.
21. Bar-Or A., Fawaz L., Fan B., Darlington P.J., Rieger A., Ghorayeb C., et al. Abnormal B-cell cytokine responses A trigger of T-cell-mediated disease in MS?. Ann. Neurol. 2010, 67:452-461.
22. Sims G.P., Ettinger R., Shirota Y., Yarboro C.H., Illei G.G., Lipsky P.E. Identification and characterization of circulating human transitional B cells. Blood 2005, 105:4390-4398.
23. von Büdingen H.C., Bar-Or A., Zamvil S.S. B cells in multiple sclerosis: connecting the dots. Curr. Opin. Immunol. 2011, 23:713-720.
24. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004, 14:164-174.
25. Magliozzi R., Howell O., Vora A., Serafini B., Nicholas R., Puopolo M., et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2006, 130:1089-1104.
26. Howell O.W., Reeves C.A., Nicholas R., Carassiti D., Radotra B., Gentleman S.M., et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011, 134:2755-2771.
27. hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010, 32:129-140.
28. Evans J.G., Chavez-Rueda K.A., Eddaoudi A., Meyer-Bahlburg A., Rawlings D.J., Ehrenstein M.R., et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J. Immunol. 2007, 178:7868-7878.
29. Roll P., Palanichamy A., Kneitz C., Dorner T., Tony H.P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006, 54:2377-2386.
30. Anolik J.H., Barnard J., Owen T., Zheng B., Kemshetti S., Looney R.J., et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007, 56:3044-3056.
31. Kasper L.H., Arnold D.L., Cohen J.A., Coles A.J., Fox E.J., Hartung H.P., et al. Lymphocyte subset dynamics following alemtuzumab treatment in the CARE-MS II study. The 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2013.
32. Corcione A., Casazza S., Ferretti E., Giunti D., Zappia E., Pistorio A., et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11064-11069.
33. Pereira J.P., Cyster J.G., Xu Y. A role for S1P and S1P1 in immature-B cell egress from mouse bone marrow. PLoS ONE 2009, 5:e9277.
34. Allende M.L., Tuymetova G., Lee B.G., Bonifacino E., Wu Y.P., Proia R.L. S1P1 receptor directs the release of immature B cells from bone marrow into blood. J. Exp. Med. 2010, 207:1113-1124.
35. Johnson T.A., Shames I., Keezer M., Lapierre Y., Haegert D.G., Bar-Or A., et al. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. Clin. Immunol. 2010, 137:15-20.
36. Mehling M., Hilbert P., Fritz S., Durovic B., Eichin D., Gasser O., et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann. Neurol. 2011, 69:408-413.